{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:50:22Z","timestamp":1793724622018,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejogrb.2018.03.044","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T13:58:16Z","timestamp":1523109496000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey"],"prefix":"10.1016","volume":"225","author":[{"given":"Francesco","family":"Plotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-520X","authenticated-orcid":false,"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Fiori","family":"Nastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"De Cicco Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2018.03.044_bib0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1055-9965.EPI-04-0871","article-title":"Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0015","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma","volume":"22","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(10)70268-0","article-title":"Sensitivity of transvaginal ultrasound for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort","volume":"12","author":"Jacobs","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/uog.1704","article-title":"How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding","volume":"24","author":"Smith-Bindman","year":"2004","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"July (7)","key":"10.1016\/j.ejogrb.2018.03.044_bib0040","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1007\/s13277-014-1836-x","article-title":"Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"issue":"December (6)","key":"10.1016\/j.ejogrb.2018.03.044_bib0045","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol"},{"issue":"August (9)","key":"10.1016\/j.ejogrb.2018.03.044_bib0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature","volume":"34","author":"Capriglione","year":"2017","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.ejogrb.2018.03.044_bib0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","article-title":"Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study","volume":"128","author":"Braicu","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"March","key":"10.1016\/j.ejogrb.2018.03.044_bib0065","article-title":"A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-Score): a single-centre, controlled study for preoperative patient selection","author":"Angioli","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"August","key":"10.1016\/j.ejogrb.2018.03.044_bib0070","article-title":"Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers","author":"Angioli","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"April (4)","key":"10.1016\/j.ejogrb.2018.03.044_bib0075","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1007\/s13277-015-4324-z","article-title":"The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program","volume":"37","author":"Angioli","year":"2016","journal-title":"Tumour Biol"},{"issue":"June (6)","key":"10.1016\/j.ejogrb.2018.03.044_bib0080","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s13277-015-3049-3","article-title":"Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a singlecenter controlled study","volume":"36","author":"Capriglione","year":"2015","journal-title":"Tumour Biol"},{"issue":"Feburary (2)","key":"10.1016\/j.ejogrb.2018.03.044_bib0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A critical review on HE4 performance in endometrial cancer: where are we now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"issue":"October (20)","key":"10.1016\/j.ejogrb.2018.03.044_bib0090","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-13-1376","article-title":"REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy","volume":"19","author":"Angioli","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"Feburary (1)","key":"10.1016\/j.ejogrb.2018.03.044_bib0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0100","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","article-title":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patiens","volume":"104","author":"Bignotti","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12885-015-1028-0","article-title":"Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance","volume":"15","author":"Brennan","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ejogrb.2018.03.044_bib0110","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/IGC.0b013e3182229ad8","article-title":"Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus","volume":"21","author":"Moore","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2011.10.025","article-title":"Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer","volume":"124","author":"Kalogera","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","article-title":"HE4 is an independent prognostic marker in endometrial cancer patients","volume":"126","author":"Mutz-Dehbalaie","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ejogrb.2018.03.044_bib0125","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0130","doi-asserted-by":"crossref","first-page":"142.el-6","DOI":"10.1016\/j.ajog.2013.04.014","article-title":"Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma","volume":"209","author":"Saarelainen","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"October (5)","key":"10.1016\/j.ejogrb.2018.03.044_bib0135","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s13277-013-0814-z","article-title":"The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients","volume":"34","author":"Omer","year":"2013","journal-title":"Tumor Biol"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0140","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1515\/cclm-2012-0373","article-title":"HE4 Study Group: HE4 in gynecological cancers: report of a European investigators and experts meeting","volume":"50","author":"Plebani","year":"2012","journal-title":"Clin Chem Lab Med"},{"issue":"January (1)","key":"10.1016\/j.ejogrb.2018.03.044_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14737140.2017.1266263","article-title":"Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4","volume":"17","author":"Capriglione","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-42542-9_7","article-title":"Obesity and endometrial cancer","volume":"208","author":"Shaw","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0155","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1469-0705.2000.00287.x","article-title":"Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group","volume":"16","author":"Timmerman","year":"2000","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"Feinstein AR A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"issue":"July (7)","key":"10.1016\/j.ejogrb.2018.03.044_bib0165","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.puhe.2015.04.017","article-title":"The effect of body mass index on endometrial cancer: a meta-analysis","volume":"129","author":"Jenabi","year":"2015","journal-title":"Public Health"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2018.03.044_bib0175","first-page":"272","article-title":"Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA 125 and SCC","volume":"5","author":"Gadducci","year":"1992","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.ejogrb.2018.03.044_bib0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1097-0142(1984)54:4<652::AID-CNCR2820540411>3.0.CO;2-C","article-title":"Immunosuppressive acidic protein in patients with gynecologic cancer","volume":"54","author":"Sawada","year":"1984","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejogrb.2018.03.044_bib0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/gyno.1994.1217","article-title":"Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma","volume":"54","author":"Takeshima","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejogrb.2018.03.044_bib0190","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/gyno.1994.1213","article-title":"Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma","volume":"54","author":"Scambia","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ejogrb.2018.03.044_bib0195","first-page":"315","article-title":"The value of serum CA 125 and association CA 125\/CA 19-9 in endometrial carcinoma","volume":"20","author":"Cherchi","year":"1999","journal-title":"Eur J Gynaecol Oncol"},{"issue":"12","key":"10.1016\/j.ejogrb.2018.03.044_bib0200","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jcp.49.12.967","article-title":"Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma","volume":"49","author":"Hareyama","year":"1996","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.ejogrb.2018.03.044_bib0205","first-page":"283","article-title":"A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma","volume":"11","author":"Gadducci","year":"1990","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2018.03.044_bib0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9378(95)90178-7","article-title":"Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen","volume":"173","author":"Hakala","year":"1995","journal-title":"Am J Obstet Gynecol"},{"issue":"6B","key":"10.1016\/j.ejogrb.2018.03.044_bib0215","first-page":"4635","article-title":"TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA125) in patients with early-stage endometrial cancer","volume":"18","author":"Peters-Engl","year":"1998","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ejogrb.2018.03.044_bib0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ijgc-00009577-200207000-00007","article-title":"Tissue and serum CA125 expression in endometrial cancer","volume":"12","author":"Ginath","year":"2002","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ejogrb.2018.03.044_bib0225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0029-7844(97)00286-X","article-title":"Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome","volume":"90","author":"Sood","year":"1997","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejogrb.2018.03.044_bib0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2002.6664","article-title":"Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?","volume":"86","author":"Hsieh","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejogrb.2018.03.044_bib0235","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/gyno.1997.4620","article-title":"Is OVX1 a suitable marker for endometrial cancer?","volume":"65","author":"Beck","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejogrb.2018.03.044_bib0240","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1996.0331","article-title":"Radiation-induced CA 125 production by mesothelial cells","volume":"63","author":"Carpenter","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"May (5)","key":"10.1016\/j.ejogrb.2018.03.044_bib0245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-017-0945-y","article-title":"Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset","volume":"34","author":"Plotti","year":"2017","journal-title":"Med Oncol"}],"container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518301428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518301428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:52:25Z","timestamp":1770655945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211518301428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":49,"alternative-id":["S0301211518301428"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.044","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}